Issue link: https://viewer.e-digitaledition.com/i/674623
or a ny where in bet ween, using r isk- factor ana lysis and an understanding of the mecha nisms behind tumor grow th to g uide ca re. " There is no such thing as over-diag- nosis, only over-treatment," Dr. Benson says. " The fact rema ins that today, in 2016, a la rge percenta ge of men dia g- nosed with prostate cancer can be safely ma naged with no initia l treatment." Dr. Benson and his colleagues use this approach, ca lled active sur veilla nce — active monitoring of the ca ncer — to prevent unnecessar y procedures, g uide schedu les of fol low-up biopsies a nd initiate ca re when wa iting is no longer in the best interest of the patient. The use of molecula r prof iling that sea rches blood for a combi nation of bioma rkers for prostate ca ncer is a key tool that helps Dr. Benson decide when wa iting is appropriate a nd when it is time for action. The test ca n identif y h a l l m a r k s o f a g g r e s s i v e c a n c e r s , assisting clinicians in decision ma king, whether it 's increa sing the frequency of biopsies or moving patients on to the nex t step — treatment. INNOVATIVE INTERVENTIONS N YP/Lawrence was the first hospita l in Westchester Count y to bring on boa rd the most recent iteration of a popula r, state-of-the-a r t robotic surger y sys- tem — a machine Dr. Benson uses to a s si s t i n t he t r eat ment of u r olog ic ca ncers such a s those of the bladder, kidneys a nd prostate. " In itia l ly, robot-a ssisted systems a l lowed us to per for m u rolog ic su r- ger y more precisely but at the cost of ef f iciency," he says. "A s the platform improves, so does the ea se a nd speed with which we ca n perform these pro- cedures. Now, the system a llows us to adjust camera angles without changing the lens, saving precious minutes during surgery. Less time on the operating table mea ns bet ter patient outcomes, but even before this improvement, I have never had to perform a blood tra nsfu- sion on a patient undergoing robotic urolog ic surger y." To prepa re for t he su rg ica l resec- tion of prostate tumors or the prostate itself, Dr. Benson utilizes high-powered M R I to col lect data about t he g la nd. K now i ng t he precise location of t he tumor, as well as whether the prostate capsule of connective tissue is intact, a nd whether the ca ncer has spread to the surrounding ly mph nodes, a llows him to pla n ef fective procedures a nd minimize side effects such as decreased sex ua l function. "Over the past five years, the magnets used in an MRI have become more pow- erful, a nd the computer that a na lyzes the tremendous wea lth of data those magnets collect has as well," Dr. Benson says. " Tailoring operations to patients' specif ic a natomy minimizes the effect we have on the ner ves a nd blood ves- sels that r un a long the sur face of the prostate. We know precisely how much tissue to remove for the best possible outcomes that eliminate ca ncer cells effectively without removing too much." ORGAN PRESERVATION AND A WIDER SCOPE The robotic surg ica l system a lso plays a star role in the remova l of kidney can- cers at NYP/Lawrence. The goal in these procedures is to remove ma lig na ncies and resolve disease while preser ving as much of the orga n as possible. Dr. Benson installs a port on a patient undergoing a robotic prostate surgical procedure. Maureen Killackey, MD, FACS, FACOG, is the Clinical Director of Cancer Services at NewYork- Presbyterian/Lawrence Hospital in Bronxville. " We h a v e k n o w n f o r y e a r s t h a t a person who donates a k id ney for a tra nspla nt is at a higher risk of devel- opi n g k id ney fa i lu re i n t he f ut u re," Dr. Benson says. "Now, we a re f inding that the best practice is to apply that infor mation to patients w it h k idney ma lignancies as well. Unless the nature of the disease is such that it ma kes this option impossible, patients should be able to reta in the kidney a f ter surg ica l resection of loca lized tumors. We ca n a lso provide patients information about orga n sa lvag ing." In novat ive i nt ravesica l i m mu no - therapy for bladder cancer has a similar goa l of orga n preser vation. Dr. Benson routinely prescribes Bacillus Ca lmette- Guerin (BCG) therapy for non-invasive, early-stage bladder cancer. BCG is deliv- ered directly to the bladder via catheter. This therapy attracts the attention of the body 's immune system to the blad- der, where the ca ncer is attacked a nd, idea lly, neutra lized by the body 's own defense mecha nism, eliminating the need for more invasive therapy. "If bladder ca ncer is more adva nced and BCG is not an option, the goa l is still to preser ve the orga n if at a ll possible," Dr. Benson says. " There has been a lot of resea rch a nd ex per i ment at ion to 0 8 0 8C O V E R F E A T U R E

